score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2803	635.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	9.0	0.0	0.2294	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat43	MEL-IPI_Pat43-Tumor-SM-4DK24	MEL-IPI_Pat43-Normal-SM-4NFVA
Putatively Actionable	Preclinical			Copy Number	FGFR1	Amplification				0.0	0.0		Putatively Actionable	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR1 Amplification		MEL-IPI_Pat43	MEL-IPI_Pat43-Tumor-SM-4DK24	
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	TTN--COL1A1			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				TTN--COL1A1 Fusion	0.0	MEL-IPI_Pat43		
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	RPL9--COL1A1			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				RPL9--COL1A1 Fusion	0.0	MEL-IPI_Pat43		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat43		
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.V950A	0.1071	252.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	4.0	0.0	0.0002	BRCA2 p.V950A (Missense)		MEL-IPI_Pat43	MEL-IPI_Pat43-Tumor-SM-4DK24	MEL-IPI_Pat43-Normal-SM-4NFVA
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.N2266S	0.102	588.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	1.0	0.0	0.0	BRCA2 p.N2266S (Missense)		MEL-IPI_Pat43	MEL-IPI_Pat43-Tumor-SM-4DK24	MEL-IPI_Pat43-Normal-SM-4NFVA
Biologically Relevant				Rearrangement	SF3B1	Fusion	HLA-B--SF3B1			0.0	0.0																					0				HLA-B--SF3B1 Fusion		MEL-IPI_Pat43		
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																					0				ESRP1 Amplification		MEL-IPI_Pat43	MEL-IPI_Pat43-Tumor-SM-4DK24	
Biologically Relevant				Copy Number	ERG	Deletion				0.0	0.0																					0				ERG Deletion		MEL-IPI_Pat43	MEL-IPI_Pat43-Tumor-SM-4DK24	
Biologically Relevant				Copy Number	ROS1	Deletion				0.0	0.0																					0				ROS1 Deletion		MEL-IPI_Pat43	MEL-IPI_Pat43-Tumor-SM-4DK24	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 Amplification, PRDM2 p.703_704insP (Insertion), nan																									0				Supporting variants: ESRP1 Amplification, PRDM2 p.703_704insP (Insertion), nan		MEL-IPI_Pat43		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.33																									0				COSMIC Signature (version 2) 1 (33%)		MEL-IPI_Pat43		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.264																									0				COSMIC Signature (version 2) 7 (26%)		MEL-IPI_Pat43		
